Novo Nordisk Foundation extends funding of reNEW

Ahead of this next phase, Node Director Kim Bak Jensen highlights the collective effort driving reNEW’s progress. “I feel genuinely privileged to work within this community. The dedication of our people has been essential to building what reNEW is today. It is our collective commitment that allows us to advance stem cell medicine and bring potential treatments closer to patients,” he said.

This commitment is strongly reflected across all three institutions. ‘I am incredibly proud of what we have been able to achieve across the three institutions hosting reNEW,’ said CEO Professor Melissa Little, AC. ‘We have been able to support the best in stem cell research whilst providing the support and environment for academics to pivot to targeted outcomes. More importantly, we are lighting the path for the next generation of researchers to play their role in improving health.’

reNEWs mission is to deliver new therapies for patients with currently untreatable diseases and believes these therapies will only come from excellence in stem cell science.

Since 2022, reNEW has supported fundamental stem cell research in almost all organ systems of the body, generated >400 scientific publications and seeded >60 targeted projects from early proof of concept to preclinical phase development.

These projects are now licensing IP to commercial partners and moving towards first in human clinical trials.

It is based on the success of this partnership that the Novo Nordisk Foundation have enthusiastically supported our continuation.

As reNEW moves into our second funding phase, we will continue to leverage our research excellence to further enable the creation of jobs and businesses developing stem cell-based products.

Topics